nNOS–CAPON blockers combined with memantine, a NMDAR blocker used in severe Alzheimer's disease, might confer more beneficial effects than memantine or nNOS–CAPON blockers alone, especially in the early stage of disease. The gene discussed is NOS1; the disease is early-onset autosomal dominant Alzheimer disease.